edito da scriptaimago il 28 Marzo 2015


[fusion_builder_container backgroundcolor="" backgroundimage="" backgroundrepeat="no-repeat" backgroundposition="left top" backgroundattachment="scroll" video_webm="" video_mp4="" video_ogv="" video_preview_image="" overlay_color="" overlay_opacity="0.5" video_mute="yes" video_loop="yes" fade="no" bordersize="0px" bordercolor="" borderstyle="" paddingtop="20px" paddingbottom="20px" paddingleft="0px" paddingright="0px" menu_anchor="" equal_height_columns="no" hundred_percent="no" class="" id=""][fusion_builder_row][fusion_builder_column type="1_1" background_position="left top" background_color="" border_size="" border_color="" border_style="solid" spacing="yes" background_image="" background_repeat="no-repeat" padding="" margin_top="0px" margin_bottom="0px" class="" id="" animation_type="" animation_speed="0.3" animation_direction="left" hide_on_mobile="no" center_content="no" min_height="none"][fusion_text]inline_64_https://servimedsrl.it/wp-content/uploads/2015/03/servimed-neuronics-logo.pngThe neuroAD system by Neuronix is an innovative, safe and effective non-pharmaceutical treatment alternative for mild to moderate Alzheimer’s Disease. It is the first medical device in the world cleared for this indication.

  • Shown to slow the degenerative progression of Alzheimer’s Disease.
  • Evidenced safe and effective in peer-reviewed studies
  • Discovered to be superior to existing pharmaceuticals in the treatment of Alzheimer’s Disease
  • Regulatory (CE) approved technology for “treatment of mild to moderate Alzheimer’s Disease”
  • Known and described in literature mechanism of action
  • Ongoing clinical trials in Alzheimer’s patients and active R&D
  • Endorsed and backed by strong Scientific Advisory Board
  • Clinical Data
    In clinical trials, neuroAD technology has shown measurable cognitive improvement after just a few weeks. The results showed marked reversal of disease progression.